STRIDES PHARMA SCIENCE LIMITED
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 52.0%
Concerns1
- Low interest coverage ratio of 1.1x
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.14 K Cr | β | βΉ2.89 K Cr | β | β | 90.4% | 14.6% | 6313.3% |
| Mar 2024 | βΉ1.87 K Cr | β | βΉ45.00 Cr | β | β | 1.3% | 0.6% | 800.0% |
| Mar 2023 | βΉ1.85 K Cr | β | βΉ5.00 Cr | β | β | 0.1% | -6.3% | -97.2% |
| Mar 2022 | βΉ1.98 K Cr | β | βΉ180.00 Cr | β | β | 5.3% | 6.5% | 130.8% |
| Mar 2021 | βΉ1.86 K Cr | β | βΉ78.00 Cr | β | β | 2.4% | 9.8% | -35.0% |
| Mar 2020 | βΉ1.69 K Cr | β | βΉ120.00 Cr | β | β | 3.8% | 10.1% | 9.1% |
| Mar 2019 | βΉ1.54 K Cr | β | βΉ110.00 Cr | β | β | 3.4% | 4.6% | -87.7% |
| Mar 2018 | βΉ1.47 K Cr | β | βΉ892.00 Cr | β | β | 28.2% | 6.4% | 718.3% |
| Mar 2017 | βΉ1.38 K Cr | β | βΉ109.00 Cr | β | β | 3.4% | -36.1% | -16.2% |
| Mar 2016 | βΉ2.16 K Cr | β | βΉ130.00 Cr | β | β | 4.1% | 132.7% | -75.6% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,128 |
| Total Expenses | 1,856 |
| EBIT / Operating Profit | 271 |
| OPM % | 13% |
| Other Income | 30 |
| Finance Costs | 123 |
| Depreciation & Amortisation | 87 |
| Profit Before Tax | 91 |
| Tax % | - |
| Net Profit / PAT | 76 |
| EPS (βΉ) | 8.30 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| STRIDES PHARMA SCIENCE LIMITEDthis co. | βΉ8.55 K Cr | βΉ2.14 K Cr | 112.00 | 2.68 | 35.54 | 14.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |